In malignant melanoma, PRMT5 suppresses the transcription of NLRC5, a key transactivator of MHC-I genes, thereby downregulating the expression of genes involved in antigen processing and presentation and impairing tumor immunogenicity [457]. Here, PRMT5 is linked to neoplasm.